Claims for Patent: 9,523,691

Summary for Patent: 9,523,691

Title:	Use of the olfactomedin-4 protein (OLFM4) in colorectal cancer diagnosis
Abstract:	The present invention provides a method for diagnosing KRAS mutations in colorectal cancers by measuring the level of OLFM4. In another aspect, the present invention relates a method of predicting the responds to a chemotherapeutic agent of a subject suffering from a colorectal cancer: according to the present invention, the by determining the OLFM4 levels. According to the present invention, the response can be predicted by determining the OLFM4 levels. This result in turn permits the design or the adaptation of a treatment of the said subject with the said chemotherapeutic agent.
Inventor(s):	Guette; Catherine (La Possonniere, FR), Coqueret; Olivier (Angers, FR), Barre; Benjamin (Brain sur Longuenee, FR), Gamelin; Erick (Paris, FR)
Assignee:	INSTITUT DE CANCEROLOGIE DE L\'OUEST (Angers, FR)
Application Number:	14/002,225
Patent Claims:	1. A method of treating colorectal cancer, comprising: (a) determining the presence of a chemotherapeutic agent-responding or non-responding phenotype of a colorectal cancer patient, said determining comprising: (i) determining the expression level of OLFM4 in a biological sample of said patient, wherein said OLFM4 expression level is determined by: measuring the amount of the glycosylated form of the olfactomedin 4 protein; measuring the amount of the non glycosylated form of the olfactomedin 4 protein; and calculating the ration of glycosylated versus non glycosylated forms of the olfactomedin 4 protein; (ii) comparing the expression level with at least one reference expression level, and (iii) determining the chemotherapeutic agent responding or non-responding phenotype, wherein an expression level in step (i) higher than the reference expression level of step (iii) indicates a non-responding phenotype; and (b) administering to the patient a dose of chemotherapeutic agent, wherein said dose is higher than 0 and wherein the phenotype determined in step (a) is a responding phenotype. 2. The method of claim 1, wherein the chemotherapeutic agent is a genotoxic drug. 3. The method of claim 2, wherein the genotoxic drug is oxaliplatin or irinotecan. 4. The method of claim 1, wherein the chemotherapeutic agent is an EGFR-targeting agent. 5. The method of claim 4, wherein the EGFR-targeting agent is a monoclonal antibody. 6. The method of claim 5, wherein the monoclonal antibody is selected from the group consisting of panitumumab and cetuximab. 7. The method of claim 1, wherein said biological sample is selected from the group consisting of a serum sample, a plasma sample, an urine sample, a blood sample, a lymph sample, and a colorectal cancer sample. 8. The method of claim 1, wherein the biological sample is a blood sample. 9. The method of claim 1, wherein the biological sample is a colorectal cancer sample. 10. The method of claim 1, wherein said expression level is measured using specific antibodies or other membrane detection technologies. 11. The method of claim 1, wherein the ratio is greater than 1.4.

Details for Patent 9,523,691

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Eli Lilly And Company	ERBITUX	cetuximab	Injection	125084	02/12/2004		2039-02-26
Eli Lilly And Company	ERBITUX	cetuximab	Injection	125084	03/28/2007		2039-02-26
Amgen, Inc.	VECTIBIX	panitumumab	Injection	125147	09/27/2006		2039-02-26